A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

(2013) S Sahebjam et al.   BRITISH JOURNAL OF CANCER

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

(2012) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

(2011) C. Twelves et al.   ANNALS OF ONCOLOGY

Preclinical Profile of a Potent  -Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

(2009) L. Luistro et al.   CANCER RESEARCH

 -Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity

(2009) R. D. Meng et al.   CANCER RESEARCH

A phase I study of an oral simulated FOLFOX with high dose capecitabine

(2009) D. Mulkerin et al.   INVESTIGATIONAL NEW DRUGS

Notch Signaling in Leukemia

(2008) Jon C. Aster et al.   Annual Review of Pathology-Mechanisms of Disease

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia

(2008) F. J.T. Staal et al.   HAEMATOLOGICA

Cancer Stem Cells and the Ontogeny of Lung Cancer

(2008) Craig D. Peacock et al.   JOURNAL OF CLINICAL ONCOLOGY

Notch signaling: Its role in epidermal homeostasis and in the pathogenesis of skin diseases

(2007) Ryuhei Okuyama et al.   JOURNAL OF DERMATOLOGICAL SCIENCE